Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.
